{"id":"W3135583340","doi":"10.1016/j.jtho.2020.11.027","title":"Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Takeda Canada; Merck Sharp and Dohme; Novartis Farmacéutica; Boehringer Ingelheim; Merck; GlaxoSmithKline; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Lung cancer; Placebo; Clinical endpoint; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Clinical trial; Adjuvant therapy; Chemotherapy; Cancer; Erlotinib; Epidermal growth factor receptor; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007151454,0.002958447,0.003789597,0.002008102,0.002354077,0.005555094,0.00318459,0.02015126,0.007752829],"category_scores_gemma":[0.02171154,0.001284819,0.003111451,0.001119281,0.001684605,0.003155315,0.0009234212,0.03365986,0.008381468],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003193319,"about_ca_system_score_gemma":0.003555061,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002767653,"about_ca_topic_score_gemma":0.007626307,"domain_scores_codex":[0.9964222,0.000590835,0.000525887,0.0003687655,0.001843668,0.0002487962],"domain_scores_gemma":[0.9837137,0.006778428,0.001060755,0.0004005263,0.005517181,0.002529292],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001183728,0.00002673219,0.00004508355,0.0002581727,0.00003971906,0.0001097033,0.000005605632,0.00004438379,0.00007555461,0.0002357557,0.9896665,0.009374459],"study_design_scores_gemma":[0.0004268377,0.0001466076,0.001175335,0.0007670958,0.0002463742,0.0003850583,0.00003577444,0.0004462168,0.0002541843,0.00174028,0.994327,0.00004914854],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00005541066,0.004590428,0.0001219903,0.04583325,0.9473689,0.00002799143,0.00008333657,0.00005025453,0.001868398],"genre_scores_gemma":[0.0005374676,0.004504439,0.0001563627,0.0466978,0.9399867,0.00002886599,0.00005785061,0.00002419658,0.008006288],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.02015126,"threshold_uncertainty_score":0.03782094,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03755095383676668,"score_gpt":0.4856211477905039,"score_spread":0.4480701939537372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}